Match tier
Likely match
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-09
S
Shoon Lei Oo
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Assistant Professor
Also affiliated: Cape Fear Valley Health System (2024–2026); Cape Fear Valley Medical Center (2024–2025)
1 h-index
7 pubs
2 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Shoon Lei Oo's research focuses on therapeutic strategies for multiple myeloma and patient outcomes. Their work includes investigating the potential of G-protein coupled receptor class C group 5 member D (GPRC5D) therapies, as highlighted in a 2026 publication. Additionally, Oo has explored the influence of genomic and clinical high-risk features on patient responses to bispecific antibody therapy in relapsed/refractory multiple myeloma, also detailed in a 2026 publication. Another publication from 2025 addresses patient perspectives on the burden of straining in constipation. Oo collaborates with researchers at the University of Arkansas for Medical Sciences, including Stefan Longobardi, Carolina Schinke, Maurizio Zangari, and Frits van Rhee, with whom they have co-authored multiple publications.
Metrics
- h-index: 1
- Publications: 7
- Citations: 2
Positions
-
Assistant Professor publications 2026University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight (2026)
-
Insights and Future Directions of GPRC5D Therapies in Multiple Myeloma (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
Collaboration Network
Top Collaborators
Stefan Longobardi
University of Arkansas for Medical Sciences (US)
3 shared publications
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
- Insights and Future Directions of GPRC5D Therapies in Multiple Myeloma
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
2 shared publications
In database
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Asis Shrestha
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Anup Kumar Trikannad
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Sruthi Vellanki
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Hira Imad Cheema
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Sanjay Muttineni
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Syed Naqvi
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Anushareddy Muddasani
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Sasya Dronavalli
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Samer Al Hadidi
Southwestern Medical Center
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Maurizio Zangari
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Frits van Rhee
Winthrop Rockefeller Foundation
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Niels Weinhold
Heidelberg University (DE)
1 shared publication
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Carolina D. Schinke
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Similar Researchers
Based on overlapping research topics
Manojna Konda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Manuel Heredia
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Health Disparities and Outcomes
Michael F. Gallagher
University of Central Arkansas
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Health Disparities and Outcomes
Kayla Hefner
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Medical Case Studies
Monica Graziutti
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Amisha Fnu
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Medical Case Studies